The Pharmaceuticals and Medical Devices Agency (PMDA) issued a risk communication update on May 30 revealing that it is gauging new safety concerns for two medicines thiamazole and desmopressin, flagging label changes in the near future. According to the update,…
To read the full story
Related Article
- MHLW Orders Label Revisions for Desmopressin, Thiamazole
June 25, 2025
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





